Atopic dermatitis

Regeneron Pharmaceuticals and Sanofi have started dosing patients in a Phase III clinical trial of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD).

LIBERTY AD CHRONOS is the first trial in the Phase III clinical programme for dupilumab and its primary objective is to show the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The LIBERTY AD Phase III clinical programme will include at least five trials of patients with moderate-to-severe AD at sites across the world.

Around 700 adult patients will be enrolled in this randomised, double-blind, placebo-controlled, multi-national trial and its secondary objectives will be to evaluate the long-term safety and efficacy of dupilumab up to 52 weeks.

"The LIBERTY AD Phase III clinical programme will include at least five trials of patients with moderate-to-severe AD at sites across the world."

National Jewish Health head of the Division of Pediatric Allergy and Immunology and member of the LIBERTY AD Clinical Trials Steering Committee Donald Leung said: "Moderate-to-severe atopic dermatitis is a serious disease characterised by severe itching, sleep disturbances and widespread rash, and existing treatment options have limited efficacy.

See Also:

"This Phase III programme will evaluate if blocking IL-4 and IL-13, two key cytokines in the Th2 inflammatory pathway, may provide a potential new approach for this chronic, difficult-to-manage disease."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Moderate-to-severe atopic dermatitis is a systemic inflammatory disease characterised by an allergic response driven by a subset of immune cells called Type 2 helper T cells, or Th2 cells.

IL-4 and IL-13 are major cytokines that are required to start and maintain this Th2 immune response.

Dupilumab was created using Regeneron’s VelocImmune technology and is being co- developed with Sanofi to treat atopic dermatitis, asthma and chronic sinusitis with nasal polyposis.

Image: Atopic dermatitis of the anterior flextural crease of the elbow. Photo: courtesy of James Heilman.